"...1","Brand_name","Drug_name_original","Drug_name","Sponsor","DrugId","Properties","Indication","Indication_EFO","DiseaseId","TA","Review_type","Year","targetIds","has_GE","Priority","Breakthrough","Accelerated","Orphan","drugType","Standard"
1,"Lutathera","Lutetium Lu 177 dotatate","LUTETIUM LU 177 DOTATATE","Advanced Accelerator Applications/Novartis","CHEMBL3989924","Somatostatin receptor-targeted radiopharmaceutical","GEP-NETs","digestive system neuroendocrine neoplasm","MONDO_0024503","Oncology","P, O",2018,"ENSG00000139874, ENSG00000162009, ENSG00000278195, ENSG00000132671, ENSG00000180616",TRUE,TRUE,FALSE,FALSE,TRUE,"Small molecule",FALSE
4,"Erleada","Apalutamide","APALUTAMIDE","Johnson & Johnson","CHEMBL3183409","Androgen receptor inhibitor","Prostate cancer","prostate cancer","MONDO_0008315","Oncology","P",2018,"ENSG00000169083",TRUE,TRUE,FALSE,FALSE,FALSE,"Small molecule",FALSE
16,"Mektovi","Binimetinib","BINIMETINIB","Array BioPharma","CHEMBL3187723","MEK inhibitor","BRAF-mutated melanoma","melanoma","EFO_0000756","Oncology","S, O",2018,"ENSG00000169032, ENSG00000126934",TRUE,FALSE,FALSE,FALSE,TRUE,"Small molecule",TRUE
17,"Braftovi","Encorafenib","ENCORAFENIB","Array BioPharma","CHEMBL3301612","BRAF inhibitor","BRAF-mutated melanoma","melanoma","EFO_0000756","Oncology","S, O",2018,"ENSG00000157764",TRUE,FALSE,FALSE,FALSE,TRUE,"Small molecule",TRUE
18,"Tibsovo","Ivosidenib","IVOSIDENIB","Agios Pharmaceuticals","CHEMBL3989958","IDH1 inhibitor","IDH1-mutated AML, Locally Advanced or Metastatic Cholangiocarcinoma (*)","acute myeloid leukemia; cholangiocarcinoma","EFO_0000222; EFO_0005221","Oncology","P, O",2018,"ENSG00000138413",TRUE,TRUE,FALSE,FALSE,TRUE,"Small molecule",FALSE
22,"Poteligeo","Mogamulizumab","MOGAMULIZUMAB","Kyowa Hakko Kirin","CHEMBL1743041","CCR4 antibody","mycosis fungoides or Sezary syndrome","mycosis fungoides","EFO_1001051","Oncology","P, O, B",2018,"ENSG00000183813",TRUE,TRUE,TRUE,FALSE,TRUE,"Antibody",FALSE
30,"Lumoxiti","Moxetumomab pasudotox","MOXETUMOMAB PASUDOTOX","AstraZeneca","CHEMBL1743043","CD22-directed antibody‚Äö√Ñ√¨drug conjugate","Hairy cell leukaemia","hairy cell leukemia","EFO_1000956","Oncology","P, O",2018,"ENSG00000167658, ENSG00000012124",TRUE,TRUE,FALSE,FALSE,TRUE,"Antibody",FALSE
32,"Copiktra","Duvelisib","DUVELISIB","Verastem","CHEMBL3039502","PI3K inhibitor","CLL, FL and SLL","chronic lymphocytic leukemia; follicular lymphoma","EFO_0000095; MONDO_0018906","Oncology","P, O, A",2018,"ENSG00000105851, ENSG00000171608",TRUE,TRUE,FALSE,TRUE,TRUE,"Small molecule",FALSE
34,"Vizimpro","Dacomitinib","DACOMITINIB","Pfizer","CHEMBL2105719","EGFR inhibitor","EGFR-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O",2018,"ENSG00000178568, ENSG00000146648, ENSG00000141736",TRUE,TRUE,FALSE,FALSE,TRUE,"Small molecule",FALSE
35,"Libtayo","Cemiplimab","CEMIPLIMAB","Regeneron/Sanofi","CHEMBL4297723","PD1 antibody","CSCC, BCC(*), NSCLC(*)","cutaneous squamous cell carcinoma; basal cell carcinoma; non-small cell lung carcinoma","EFO_1001927; EFO_0004193; EFO_0003060","Oncology","P, B",2018,"ENSG00000188389",TRUE,TRUE,TRUE,FALSE,FALSE,"Antibody",FALSE
38,"Talzenna","Talazoparib","TALAZOPARIB","Pfizer","CHEMBL3137320","PARP inhibitor","BRCA-mutated HER2-negative breast cancer","HER2 negative breast carcinoma","EFO_0009780","Oncology","P",2018,"ENSG00000143799, ENSG00000129484",TRUE,TRUE,FALSE,FALSE,FALSE,"Small molecule",FALSE
39,"Lorbrena","Lorlatinib","LORLATINIB","Pfizer","CHEMBL3286830","ALK and ROS1 inhibitor","ALK-positive NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2018,"ENSG00000171094, ENSG00000143924",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
42,"Daurismo","Glasdegib","GLASDEGIB","Pfizer","CHEMBL2043437","Hedgehog pathway inhibitor","AML",NA,"EFO_0000222","Oncology","P, O",2018,"ENSG00000128602",TRUE,TRUE,FALSE,FALSE,TRUE,"Small molecule",FALSE
43,"Vitrakvi","Larotrectinib","LAROTRECTINIB","Loxo Oncology/Bayer","CHEMBL3889654","TRKA, TRKB and TRKC inhibitor","NTRK-positive solid cancers","salivary gland cancer; soft tissue sarcoma; thyroid cancer","MONDO_0004669; EFO_1001968; MONDO_0002108","Oncology","P, O, B, A",2018,"ENSG00000148053, ENSG00000198400, ENSG00000140538",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
44,"Xospata","Gilteritinib","GILTERITINIB","Astellas","CHEMBL3301622","FLT3 inhibitor","FLT3-positive AML","acute myeloid leukemia","EFO_0000222","Oncology","P, O, B",2018,"ENSG00000122025, ENSG00000167601",TRUE,TRUE,TRUE,FALSE,TRUE,"Small molecule",FALSE
47,"Asparlas","Calaspargase pegol","CALASPARGASE PEGOL","Servier","CHEMBL2108728","Asparagine specific enzyme","ALL","acute lymphoblastic leukemia","EFO_0000220","Oncology","S, O",2018,"ENSG00000166183",FALSE,FALSE,FALSE,FALSE,TRUE,"Enzyme",TRUE
49,"Elzonris","Tagraxofusp","TAGRAXOFUSP","Stemline Therapeutics","CHEMBL4297573","IL-3 and diphtheria toxin fusion protein","Blastic plasmacytoid dendritic cell neoplasm","blastic plasmacytoid dendritic cell neoplasm","EFO_0010580","Oncology","P, O, B",2018,"ENSG00000167658, ENSG00000185291",FALSE,TRUE,TRUE,FALSE,TRUE,"Protein",FALSE
56,"Balversa","Erdafitinib","ERDAFITINIB","Janssen /J&J","CHEMBL3545376","FGFR inhibitor","Bladder cancer","urinary bladder carcinoma","MONDO_0004986","Oncology","P, B, A",2019,"ENSG00000077782, ENSG00000066468, ENSG00000160867, ENSG00000068078",TRUE,TRUE,TRUE,TRUE,FALSE,"Small molecule",FALSE
59,"Piqray","Alpelisib","ALPELISIB","Novartis","CHEMBL2396661","PI3K inhibitor","Breast cancer","breast cancer","MONDO_0007254","Oncology","P",2019,"ENSG00000121879",TRUE,TRUE,FALSE,FALSE,FALSE,"Small molecule",FALSE
60,"Polivy","Polatuzumab vedotin","POLATUZUMAB VEDOTIN","Roche","CHEMBL3301582","CD79b-directed ADC","Diffuse large B-cell lymphoma","diffuse large b-cell lymphoma","EFO_0000403","Oncology","P, O, B, A",2019,"ENSG00000198033, ENSG00000167552, ENSG00000261456, ENSG00000176014, ENSG00000258947, ENSG00000123416, ENSG00000101162, ENSG00000188229, ENSG00000152086, ENSG00000007312, ENSG00000137285, ENSG00000167553, ENSG00000196230, ENSG00000137267, ENSG00000127824, ENSG00000104833",TRUE,TRUE,TRUE,TRUE,TRUE,"Antibody",FALSE
62,"Xpovio","Selinexor","SELINEXOR","Karyopharm Therapeutics","CHEMBL3545185","XPO1 inhibitor","Multiple myeloma","multiple myeloma","EFO_0001378","Oncology","P, O, A",2019,"ENSG00000082898",TRUE,TRUE,FALSE,TRUE,TRUE,"Small molecule",FALSE
64,"Nubeqa","Darolutamide","DAROLUTAMIDE","Bayer","CHEMBL4297185","Androgen receptor inhibitor","Prostate cancer","prostate cancer","MONDO_0008315","Oncology","P",2019,"ENSG00000169083",TRUE,TRUE,FALSE,FALSE,FALSE,"Small molecule",FALSE
65,"Turalio","Pexidartinib","PEXIDARTINIB","Daiichi Sankyo","CHEMBL3813873","CSF1R, KIT and FLT3 inhibitor","Tenosynovial giant cell tumour","Tenosynovial Giant Cell Tumor","EFO_1000562","Oncology","P, O, B",2019,"ENSG00000182578, ENSG00000122025, ENSG00000157404",TRUE,TRUE,TRUE,FALSE,TRUE,"Small molecule",FALSE
67,"Rozlytrek","Entrectinib","ENTRECTINIB","Roche","CHEMBL1983268","TRKA, TRKB, TRKC, ROS1 and ALK inhibitor","NTRK fusion-positive solid tumours and ROS1-positive NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2019,"ENSG00000148053, ENSG00000198400, ENSG00000140538, ENSG00000047936, ENSG00000171094",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
81,"Brukinsa","Zanubrutinib","ZANUBRUTINIB","BeiGene","CHEMBL3936761","BTK inhibitor","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Oncology","P, O, B, A",2019,"ENSG00000010671",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
87,"Padcev","Enfortumab vedotin","ENFORTUMAB VEDOTIN","Astellas","CHEMBL3301589","Nectin-4-directed ADC","Urothelial cancers","urothelial neoplasm","MONDO_0024337","Oncology","P, B, A",2019,"ENSG00000143217, ENSG00000101162, ENSG00000167552, ENSG00000261456, ENSG00000127824, ENSG00000123416, ENSG00000258947, ENSG00000198033, ENSG00000188229, ENSG00000152086, ENSG00000137267, ENSG00000104833, ENSG00000167553, ENSG00000137285, ENSG00000196230, ENSG00000176014",TRUE,TRUE,TRUE,TRUE,FALSE,"Antibody",FALSE
89,"Enhertu","Trastuzumab deruxtecan","TRASTUZUMAB DERUXTECAN","Daiichi Sankyo/AstraZeneca","CHEMBL4297844","HER2-directed ADC","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Oncology","P, B, A",2019,"ENSG00000141736, ENSG00000198900",TRUE,TRUE,TRUE,TRUE,FALSE,"Antibody",FALSE
92,"Ayvakit","Avapritinib","AVAPRITINIB","Blueprint Medicines","CHEMBL4204794","PDGFRA, PDGFRA mutants and KIT kinase inhibitor","GIST with PDGFRA exon 18 mutations","gastrointestinal stromal tumor","MONDO_0011719","Oncology","P, O, B",2020,"ENSG00000157404, ENSG00000134853",TRUE,TRUE,TRUE,FALSE,TRUE,"Small molecule",FALSE
94,"Tazverik","Tazemetostat","TAZEMETOSTAT","Epizyme","CHEMBL3414621","EZH2 inhibitor","Epithelioid sarcoma","epithelioid sarcoma","MONDO_0017387","Oncology","P, O, A",2020,"ENSG00000106462",TRUE,TRUE,FALSE,TRUE,TRUE,"Small molecule",FALSE
99,"Sarclisa","Isatuximab","ISATUXIMAB","Sanofi","CHEMBL3545131","CD38-directed mAb","Multiple myeloma","multiple myeloma","EFO_0001378","Oncology","S, O",2020,"ENSG00000004468",TRUE,FALSE,FALSE,FALSE,TRUE,"Antibody",TRUE
103,"Tukysa","Tucatinib","TUCATINIB","Seagen","CHEMBL3989868","HER2 kinase inhibitor","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Oncology","P, O, B",2020,"ENSG00000141736",TRUE,TRUE,TRUE,FALSE,TRUE,"Small molecule",FALSE
104,"Pemazyre","Pemigatinib","PEMIGATINIB","Incyte","CHEMBL4297522","FGFR1-3 kinase inhibitor","Cholangiocarcinoma","cholangiocarcinoma","EFO_0005221","Oncology","P, O, B, A",2020,"ENSG00000066468, ENSG00000068078, ENSG00000077782",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
105,"Trodelvy","Sacituzumab govitecan","SACITUZUMAB GOVITECAN","Immunomedics/Gilead","CHEMBL3545262","TROP2-directed ADC, with topoisomerase inhibitor","Triple-negative breast cancer (and advanced or metastatic urothelial cancer (mUC)*)","triple-negative breast cancer; urothelial carcinoma","EFO_0005537; EFO_0008528","Oncology","P, B, A",2020,"ENSG00000198900, ENSG00000184292",TRUE,TRUE,TRUE,TRUE,FALSE,"Antibody",FALSE
107,"Tabrecta","Capmatinib","CAPMATINIB","Novartis","CHEMBL3188267","MET kinase inhibitor","NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2020,"ENSG00000105976",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
108,"Retevmo","Selpercatinib","SELPERCATINIB","Eli Lilly/Loxo Oncology","CHEMBL4559134","RET kinase inhibitor","RET fusion-positive NSCLC and thyroid cancer","non-small cell lung carcinoma; thyroid cancer","EFO_0003060; MONDO_0002108","Oncology","P, O, B, A",2020,"ENSG00000108091, ENSG00000165731, ENSG00000170759",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
109,"Qinlock","Ripretinib","RIPRETINIB","Deciphera","CHEMBL4216467","KIT and PDGFRA kinase inhibitor","GIST","gastrointestinal stromal tumor","MONDO_0011719","Oncology","P, O, B",2020,"ENSG00000157404, ENSG00000134853",TRUE,TRUE,TRUE,FALSE,TRUE,"Small molecule",FALSE
116,"Monjuvi","Tafasitamab","TAFASITAMAB","MorphoSys","CHEMBL4298047","CD19-directed mAb","DLBCL","diffuse large b-cell lymphoma","EFO_0000403","Oncology","P, O, B, A",2020,"ENSG00000177455",TRUE,TRUE,TRUE,TRUE,TRUE,"Antibody",FALSE
117,"Blenrep","Belantamab mafodotin","BELANTAMAB MAFODOTIN","GlaxoSmithKline","CHEMBL4298209","BCMA-directed ADC, with microtubule inhibitor","Multiple myeloma","multiple myeloma","EFO_0001378","Oncology","P, O, B, A",2020,"ENSG00000048462, ENSG00000152086, ENSG00000167553, ENSG00000188229, ENSG00000137267, ENSG00000176014, ENSG00000261456, ENSG00000127824, ENSG00000123416, ENSG00000137285, ENSG00000258947, ENSG00000167552, ENSG00000198033, ENSG00000196230, ENSG00000104833, ENSG00000101162",TRUE,TRUE,TRUE,TRUE,TRUE,"Antibody",FALSE
125,"Gavreto","Pralsetinib","PRALSETINIB","Blueprint Medicines/Roche","CHEMBL4582651","RET kinase inhibitor","RET fusion-positive NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2020,"ENSG00000170759, ENSG00000165731, ENSG00000108091",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
132,"Margenza","Margetuximab","MARGETUXIMAB","MacroGenics","CHEMBL2364649","HER2-directed mAb","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Oncology","S",2020,"ENSG00000141736",TRUE,FALSE,FALSE,FALSE,FALSE,"Antibody",TRUE
133,"Orgovyx","Relugolix","RELUGOLIX","Myovant Sciences","CHEMBL1800159","GnRH receptor antagonist","Prostate cancer","prostate cancer","MONDO_0008315","Oncology","P",2020,"ENSG00000109163",TRUE,TRUE,FALSE,FALSE,FALSE,"Small molecule",FALSE
137,"Tepmetko","Tepotinib","Tepotinib","EMD Serono","CHEMBL3402762","MET kinase inhibitor","NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, A",2021,"ENSG00000105976",TRUE,TRUE,FALSE,TRUE,TRUE,"Small molecule",FALSE
138,"Ukoniq","Umbralisib","Umbralisib","TG Therapeutics","CHEMBL3948730","PI3Kdelta and CK1epsilon inhibitor","MZL, follicular lymphoma","MZL; follicular lymphoma","EFO_1000630; MONDO_0018906","Oncology","P, O, B, A",2021,"ENSG00000171608, ENSG00000097007, ENSG00000213923",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
140,"Cosela","Trilaciclib","Trilaciclib","G1 Therapeutics","CHEMBL3894860","CDK4 and CDK6 kinase inhibitor","Chemotherapy-induced myelosuppression","myelosuppression; small cell lung carcinoma","EFO_0007053; EFO_0000702","Oncology","P, B",2021,"ENSG00000135446, ENSG00000105810",TRUE,TRUE,TRUE,FALSE,FALSE,"Small molecule",FALSE
145,"Fotivda","Tivozanib","Tivozanib","Aveo","CHEMBL1289494","VEGFR kinase inhibitor","Renal cell carcinoma","renal cell carcinoma","EFO_0000681","Oncology","S",2021,"ENSG00000102755, ENSG00000128052, ENSG00000037280, ENSG00000157404, ENSG00000113721",TRUE,FALSE,FALSE,FALSE,FALSE,"Small molecule",TRUE
151,"Jemperli","Dostarlimab","Dostarlimab","GlaxoSmithKline","CHEMBL4298124","PD1-targeted mAb","Endometrial cancer","endometrial cancer","MONDO_0011962","Oncology","P, B, A",2021,"ENSG00000188389",TRUE,TRUE,TRUE,TRUE,FALSE,"Antibody",FALSE
152,"Zynlonta","Loncastuximab tesirine","Loncastuximab tesirine","ADC Therapeutics","CHEMBL4297778","CD19-targeted ADC","B-cell lymphoma","B-cell non-Hodgkins lymphoma","EFO_1001938","Oncology","P, O, A",2021,"ENSG00000177455",TRUE,TRUE,FALSE,TRUE,TRUE,"Antibody",FALSE
154,"Rybrevant","Amivantamab","Amivantamab","J&J","CHEMBL4297774","EGFRxMETR bispecific antibody","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, B, A",2021,"ENSG00000105976, ENSG00000146648",TRUE,TRUE,TRUE,TRUE,FALSE,"Antibody",FALSE
156,"Truseltiq","Infigratinib","Infigratinib","BridgeBio","CHEMBL1852688","FGFR2 kinase inhibitor","FGFR2-mutated bile duct cancer","bile duct cancer","MONDO_0003059","Oncology","P, O, A",2021,"ENSG00000160867, ENSG00000068078, ENSG00000066468, ENSG00000077782",TRUE,TRUE,FALSE,TRUE,TRUE,"Small molecule",FALSE
157,"Lumakras","Sotorasib","Sotorasib","Amgen","CHEMBL4535757","KRAS-G12C inhibitor","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2021,"ENSG00000133703",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
166,"Welireg","Belzutifan","Belzutifan","Merck & Co.","CHEMBL4585668","HIF-2alpha inhibitor","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Oncology","P, O",2021,"ENSG00000116016",TRUE,TRUE,FALSE,FALSE,TRUE,"Small molecule",FALSE
169,"Exkivity","Mobocertinib","Mobocertinib","Takeda","CHEMBL4650319","EGFR kinase inhibitor","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2021,"ENSG00000146648",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
170,"Tivdak","Tisotumab vedotin","Tisotumab vedotin","Seagen/Genmab","CHEMBL4297841","Tissue-factor-directed ADC","Cervical cancer","cervical cancer","MONDO_0002974","Oncology","P, A",2021,"ENSG00000117525, ENSG00000167552, ENSG00000258947, ENSG00000137267, ENSG00000188229, ENSG00000176014, ENSG00000261456, ENSG00000123416, ENSG00000198033, ENSG00000196230, ENSG00000167553, ENSG00000152086, ENSG00000104833, ENSG00000137285, ENSG00000101162, ENSG00000127824",TRUE,TRUE,FALSE,TRUE,FALSE,"Antibody",FALSE
174,"Scemblix","Asciminib","Asciminib","Novartis","CHEMBL4208229","ABL/BCR-ABL1  kinase inhibitor","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Oncology","P, O, B, A",2021,"ENSG00000097007",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
175,"Besremi","Ropeginterferon alfa-2b","Ropeginterferon alfa-2b","Pharmaessentia","CHEMBL4297819","PEGylated interferon alpha-2b","Polycythaemia vera","polycythemia vera","EFO_0002429","Oncology","S, O",2021,"ENSG00000142166, ENSG00000159110",TRUE,FALSE,FALSE,FALSE,TRUE,"Protein",TRUE
183,"Krazati","Adagrasib","Adagrasib","Mirati","CHEMBL4594350","KRAS-G12C inhibitor","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","S, O, B, A",2022,"ENSG00000133703",TRUE,FALSE,TRUE,TRUE,TRUE,"Small molecule",TRUE
189,"Lytgobi","Futibatinib","Futibatinib","Taiho Oncology","CHEMBL3701238","FGFR kinase inhibitor","FGFR2-aberrant intrahepatic cholangiocarcinoma","intrahepatic cholangiocarcinoma","EFO_1001961","Oncology","P, O, B, A",2022,"ENSG00000068078, ENSG00000077782, ENSG00000160867, ENSG00000066468",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
191,"Pluvicto","Lutetium Lu-177 vipivotide tetraxetan","Lutetium Lu-177 vipivotide tetraxetan","Novartis","CHEMBL4594406","PSMA-binding radioligand therapeutic agent","PSMA-positive prostate cancer","prostate carcinoma","EFO_0001663","Oncology","P, B",2022,"ENSG00000142515",TRUE,TRUE,TRUE,FALSE,FALSE,"Small molecule",FALSE
193,"Elahere","Mirvetuximab soravtansine","Mirvetuximab soravtansine","ImmunoGen","CHEMBL3545132","FR_-targeted antibody-drug conjugate","Ovarian cancer","ovarian carcinoma","EFO_0001075","Oncology","P, O, A",2022,"ENSG00000110195, ENSG00000127824, ENSG00000152086, ENSG00000261456, ENSG00000101162, ENSG00000188229, ENSG00000104833, ENSG00000258947, ENSG00000123416, ENSG00000198033, ENSG00000167553, ENSG00000137285, ENSG00000167552, ENSG00000176014, ENSG00000137267, ENSG00000196230",TRUE,TRUE,FALSE,TRUE,TRUE,"Antibody",FALSE
195,"Lunsumio","Mosunetuzumab","Mosunetuzumab","Roche/Genentech","CHEMBL4297788","CD20 _ CD3 bispecific antibody","Follicular lymphoma","follicular lymphoma","MONDO_0018906","Oncology","P, O, B, A",2022,"ENSG00000167286, ENSG00000156738, ENSG00000198851, ENSG00000160654",TRUE,TRUE,TRUE,TRUE,TRUE,"Antibody",FALSE
197,"Rezlidhia","Olutasidenib","Olutasidenib","Rigel/Forma","CHEMBL4297610","IDH1 inhibitor","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Oncology","S, O",2022,"ENSG00000138413",TRUE,FALSE,FALSE,FALSE,TRUE,"Small molecule",TRUE
199,"Vonjo","Pacritinib","Pacritinib","CTI Biopharma","CHEMBL2035187","JAK2 inhibitor","Myelofibrosis","myelofibrosis","MONDO_0044903","Oncology","P, O, A",2022,"ENSG00000096968, ENSG00000122025",TRUE,TRUE,FALSE,TRUE,TRUE,"Small molecule",FALSE
200,"Opdualag","Relatlimab; nivolumab","Relatlimab","Bristol Myers Squibb","CHEMBL3990044","LAG3-targeted mAb plus PD1-targeted mAb","Melanoma","melanoma","EFO_0000756","Oncology","P, O",2022,"ENSG00000089692",TRUE,TRUE,FALSE,FALSE,TRUE,"Antibody",FALSE
205,"Kimmtrak","Tebentafusp","Tebentafusp","Immunocore","CHEMBL4297990","gp100 peptide HLA _ CD3 bispecific T-cell engager","Uveal melanoma","Uveal Melanoma","EFO_1000616","Oncology","P, O, B",2022,"ENSG00000185664",FALSE,TRUE,TRUE,FALSE,TRUE,"Protein",FALSE
206,"Tecvayli","Teclistamab","Teclistamab","J&J","CHEMBL4594505","BCMA _ CD3 bispecific antibody","Multiple myeloma","multiple myeloma","EFO_0001378","Oncology","P, O, B, A",2022,"ENSG00000048462, ENSG00000160654, ENSG00000198851, ENSG00000167286",TRUE,TRUE,TRUE,TRUE,TRUE,"Antibody",FALSE
210,"Imjudo","Tremelimumab","Tremelimumab","AstraZeneca","CHEMBL2108658","CTLA4-targeted mAb","Hepatocellular carcinoma","hepatocellular carcinoma","EFO_0000182","Oncology","S, O",2022,"ENSG00000163599",TRUE,FALSE,FALSE,FALSE,TRUE,"Antibody",TRUE
218,"Kisqali","Ribociclib","RIBOCICLIB","Novartis","CHEMBL3545110","CDK4/6 inhibitor","HR-positive, HER2-negative breast cancer","HER2 negative breast carcinoma","EFO_0009780","Oncology","P, B",2017,"ENSG00000105810, ENSG00000135446",TRUE,TRUE,TRUE,FALSE,FALSE,"Small molecule",FALSE
221,"Bavencio","Avelumab","AVELUMAB","Merck KGaA/Pfizer","CHEMBL3833373","PDL1-blocking antibody","Merkel cell carcinoma","Merkel cell skin cancer","EFO_1001471","Oncology","P, O, B, A",2017,"ENSG00000120217",TRUE,TRUE,TRUE,TRUE,TRUE,"Antibody",FALSE
222,"Zejula","Niraparib","NIRAPARIB","Tesaro","CHEMBL1094636","PARP inhibitor","Epithelial ovarian, fallopian tube or primary peritoneal cancer","fallopian tube cancer; ovarian epithelial tumor; primary peritoneal carcinoma","MONDO_0002158; MONDO_0002229; MONDO_0015686","Oncology","P, O, B",2017,"ENSG00000129484, ENSG00000143799",TRUE,TRUE,TRUE,FALSE,TRUE,"Small molecule",FALSE
228,"Rydapt","Midostaurin","MIDOSTAURIN","Novartis","CHEMBL608533","FLT3 inhibitor","FLT3-positive AML","acute myeloid leukemia, FLT3 internal tandem duplication","MONDO_0100415","Oncology","P, O, B",2017,"ENSG00000163932, ENSG00000115825, ENSG00000166501, ENSG00000171132, ENSG00000163558, ENSG00000184304, ENSG00000065675, ENSG00000126583, ENSG00000027075, ENSG00000067606, ENSG00000154229, ENSG00000128052, ENSG00000122025, ENSG00000157404, ENSG00000134853, ENSG00000113721",TRUE,TRUE,TRUE,FALSE,TRUE,"Small molecule",FALSE
230,"Alunbrig","Brigatinib","BRIGATINIB","Ariad Pharmaceuticals/Takeda","CHEMBL3545311","ALK inhibitor","ALK-positive NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2017,"ENSG00000171094, ENSG00000146648",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
231,"Imfinzi","Durvalumab","DURVALUMAB","AstraZeneca","CHEMBL3301587","PDL1-blocking antibody","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Oncology","P, B, A",2017,"ENSG00000120217",TRUE,TRUE,TRUE,TRUE,FALSE,"Antibody",FALSE
235,"Nerlynx","Neratinib","NERATINIB","Puma Biotechnology","CHEMBL180022","EGFR, HER2 and HER4 irreversible kinase inhibitor","HER2-overexpressed breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Oncology","S",2017,"ENSG00000178568, ENSG00000146648, ENSG00000141736",TRUE,FALSE,FALSE,FALSE,FALSE,"Small molecule",TRUE
236,"Idhifa","Enasidenib mesylate","ENASIDENIB MESYLATE","Celgene/Agios","CHEMBL3989931","IDH2 inhibitor","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Oncology","P, O",2017,"ENSG00000182054",TRUE,TRUE,FALSE,FALSE,TRUE,"Small molecule",FALSE
237,"Besponsa","Inotuzumab ozogamicin","INOTUZUMAB OZOGAMICIN","Pfizer","CHEMBL2108611","CD22-directed antibody‚Äö√Ñ√¨drug conjugate","B cell precursor ALL","precursor B-cell acute lymphoblastic leukemia","MONDO_0020511","Oncology","P, O, B",2017,"ENSG00000012124",TRUE,TRUE,TRUE,FALSE,TRUE,"Antibody",FALSE
238,"Aliqopa","Copanlisib dihydrochloride","COPANLISIB","Bayer","CHEMBL3218576","PI3Kalpha/≈í¬• inhibitor","Follicular lymphoma","follicular lymphoma","MONDO_0018906","Oncology","P, O, A",2017,"ENSG00000171608, ENSG00000121879",TRUE,TRUE,FALSE,TRUE,TRUE,"Small molecule",FALSE
239,"Verzenio","Abemaciclib","ABEMACICLIB","Eli Lilly","CHEMBL3301610","CDK4/6 inhibitor","HR-positive, HER2-negative breast cancer","HER2 negative breast carcinoma","EFO_0009780","Oncology","P, B",2017,"ENSG00000105810, ENSG00000135446",TRUE,TRUE,TRUE,FALSE,FALSE,"Small molecule",FALSE
240,"Calquence","Acalabrutinib","ACALABRUTINIB","AstraZeneca/Acerta Pharma","CHEMBL3707348","BTK inhibitor","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Oncology","P, O, B, A",2017,"ENSG00000010671",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
254,"Venclexta","Venetoclax","VENETOCLAX","AbbVie","CHEMBL3137309","BCL-2 inhibitor","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Oncology","P, O, B, A",2016,"ENSG00000171791",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
256,"Tecentriq","Atezolizumab","ATEZOLIZUMAB","Genentech","CHEMBL3707227","PDL1 inhibitor","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Oncology","P, B, A",2016,"ENSG00000120217",TRUE,TRUE,TRUE,TRUE,FALSE,"Antibody",FALSE
264,"Lartruvo","Olaratumab","OLARATUMAB","Eli Lilly","CHEMBL1743049","PDGFRalpha-blocking antibody","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Oncology","P, O, B, A",2016,"ENSG00000134853",TRUE,TRUE,TRUE,TRUE,TRUE,"Antibody",FALSE
266,"Rubraca","Rucaparib","RUCAPARIB","Clovis Oncology","CHEMBL1173055","PARP inhibitor","BRCA-positive ovarian cancer","ovarian cancer","MONDO_0008170","Oncology","P, O, B, A",2016,"ENSG00000041880, ENSG00000129484, ENSG00000143799",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
276,"Cyramza","Ramucirumab","RAMUCIRUMAB","Eli Lilly","CHEMBL1743062","VEGFR2 antagonist","Gastric cancer","gastric cancer","MONDO_0001056","Oncology","P, O",2014,"ENSG00000128052",TRUE,TRUE,FALSE,FALSE,TRUE,"Antibody",FALSE
278,"Zykadia","Ceritinib","CERITINIB","Novartis","CHEMBL2403108","Kinase inhibitor against ALK, IGF1R, insulin receptor and ROS1","ALK-positive metastatic NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2014,"ENSG00000171094, ENSG00000143924, ENSG00000181163",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
288,"Keytruda","Pembrolizumab","PEMBROLIZUMAB","Merck & Co.","CHEMBL3137343","PD1-specific antibody","Metastatic melanoma *and others (2021 approval)","metastatic melanoma","EFO_0002617","Oncology","P, O, B, A",2014,"ENSG00000188389, ENSG00000120217",TRUE,TRUE,TRUE,TRUE,TRUE,"Antibody",FALSE
294,"Blincyto","Blinatumomab","BLINATUMOMAB","Amgen","CHEMBL1742992","CD19- and CD3-bispecific antibody","B-ALL","precursor B-cell acute lymphoblastic leukemia","MONDO_0020511","Oncology","P, O, B, A",2014,"ENSG00000177455, ENSG00000160654, ENSG00000167286, ENSG00000198851",TRUE,TRUE,TRUE,TRUE,TRUE,"Antibody",FALSE
295,"Lynparza","Olaparib","OLAPARIB","AstraZeneca","CHEMBL521686","PARP inhibitor","Advanced BRCA-mutated ovarian cancer","ovarian cancer","MONDO_0008170","Oncology","P, O, A",2014,"ENSG00000143799, ENSG00000041880, ENSG00000129484",TRUE,TRUE,FALSE,TRUE,TRUE,"Small molecule",FALSE
296,"Opdivo","Nivolumab","NIVOLUMAB","Bristol-Myers Squibb","CHEMBL2108738","PD1 inhibitor","Unresectable or metastatic melanoma","metastatic melanoma","EFO_0002617","Oncology","P, O, B, A",2014,"ENSG00000188389, ENSG00000120217",TRUE,TRUE,TRUE,TRUE,TRUE,"Antibody",FALSE
300,"Ibrance","Palbociclib","PALBOCICLIB","Pfizer","CHEMBL189963","CDK4 and CDK6 inhibitor","ER-positive, HER2-negative advanced breast cancer","HER2 negative breast carcinoma","EFO_0009780","Oncology","P, B, A",2015,"ENSG00000135446, ENSG00000110092, ENSG00000105810",TRUE,TRUE,TRUE,TRUE,FALSE,"Small molecule",FALSE
301,"Lenvima","Lenvatinib","LENVATINIB","Eisai","CHEMBL1289601","VEGFR inhibitor","Thyroid cancer","thyroid cancer","MONDO_0002108","Oncology","P, O",2015,"ENSG00000037280, ENSG00000128052, ENSG00000102755",TRUE,TRUE,FALSE,FALSE,TRUE,"Small molecule",FALSE
302,"Farydak","Panobinostat","PANOBINOSTAT","Novartis","CHEMBL483254","Histone deacetylase inhibitor","Multiple myeloma","multiple myeloma","EFO_0001378","Oncology","P, O, A",2015,"ENSG00000100429, ENSG00000196591, ENSG00000163517, ENSG00000061273, ENSG00000068024, ENSG00000048052, ENSG00000116478, ENSG00000108840, ENSG00000094631, ENSG00000171720, ENSG00000147099",TRUE,TRUE,FALSE,TRUE,TRUE,"Small molecule",FALSE
312,"Odomzo","Sonidegib","SONIDEGIB","Novartis","CHEMBL2105737","Smoothened inhibitor","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Oncology","S",2015,"ENSG00000128602",TRUE,FALSE,FALSE,FALSE,FALSE,"Small molecule",TRUE
317,"Lonsurf","Tipiracil; trifluridine","TIPIRACIL","Taiho","CHEMBL235668","Thymidine phosphorylase inhibitor plus a nucleoside metabolic inhibitor","Colorectal cancer","colorectal cancer","EFO_0005842","Oncology","S",2015,"ENSG00000025708",TRUE,FALSE,FALSE,FALSE,FALSE,"Small molecule",TRUE
323,"Cotellic","Cobimetinib","COBIMETINIB","Genentech","CHEMBL2146883","MEK inhibitor","Melanoma with BRAFV600E/K mutations","melanoma","EFO_0000756","Oncology","P, O",2015,"ENSG00000126934, ENSG00000169032",TRUE,TRUE,FALSE,FALSE,TRUE,"Small molecule",FALSE
324,"Tagrisso","Osimertinib","OSIMERTINIB","AstraZeneca","CHEMBL3353410","EGFR inhibitor","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2015,"ENSG00000146648",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
325,"Darzalex","Daratumumab","DARATUMUMAB","Johnson & Johnson","CHEMBL1743007","CD38-directed mAb","Multiple myeloma","multiple myeloma","EFO_0001378","Oncology","P, O, B, A",2015,"ENSG00000004468",TRUE,TRUE,TRUE,TRUE,TRUE,"Antibody",FALSE
326,"Ninlaro","Ixazomib","IXAZOMIB","Takeda","CHEMBL2141296","Oral proteasome inhibitor","Multiple myeloma","multiple myeloma","EFO_0001378","Oncology","P, O",2015,"ENSG00000165916, ENSG00000240065, ENSG00000159377, ENSG00000108671, ENSG00000100804, ENSG00000161057, ENSG00000154611, ENSG00000159352, ENSG00000100902, ENSG00000013275, ENSG00000173692, ENSG00000101182, ENSG00000103035, ENSG00000129084, ENSG00000142507, ENSG00000222028, ENSG00000197170, ENSG00000175166, ENSG00000205220, ENSG00000100764, ENSG00000277791, ENSG00000136930, ENSG00000099341, ENSG00000163636, ENSG00000185627, ENSG00000127922, ENSG00000115233, ENSG00000087191, ENSG00000108344, ENSG00000204264, ENSG00000100519, ENSG00000100567, ENSG00000143106, ENSG00000126067, ENSG00000130706, ENSG00000106588, ENSG00000008018, ENSG00000041357",TRUE,TRUE,FALSE,FALSE,TRUE,"Small molecule",FALSE
327,"Portrazza","Necitumumab","NECITUMUMAB","Eli Lilly","CHEMBL1743047","EGFR antagonist","NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","S, O",2015,"ENSG00000146648",TRUE,FALSE,FALSE,FALSE,TRUE,"Antibody",TRUE
328,"Empliciti","Elotuzumab","ELOTUZUMAB","Bristol-Myers Squibb","CHEMBL1743010","SLAMF7-directed mAb","Multiple myeloma","multiple myeloma","EFO_0001378","Oncology","P, O, B",2015,"ENSG00000026751",TRUE,TRUE,TRUE,FALSE,TRUE,"Antibody",FALSE
330,"Alecensa","Alectinib","ALECTINIB","Roche","CHEMBL1738797","ALK inhibitor","NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2015,"ENSG00000171094, ENSG00000143924, ENSG00000165731",TRUE,TRUE,TRUE,TRUE,TRUE,"Small molecule",FALSE
335,"Pomalyst","Pomalidomide","POMALIDOMIDE","Celgene","CHEMBL43452","Immunomodulatory antineoplastic agent","Multiple myeloma","multiple myeloma","EFO_0001378","Oncology","S, O",2013,"ENSG00000167986, ENSG00000139842, ENSG00000113851, ENSG00000100387",TRUE,FALSE,FALSE,FALSE,TRUE,"Small molecule",TRUE
336,"Kadcyla","Ado-trastuzumab emtansine","TRASTUZUMAB EMTANSINE","Genentech","CHEMBL1743082","HER2-targeted antibody and microtubule inhibitor conjugate","HER2-positive metastatic breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Oncology","P",2013,"ENSG00000167553, ENSG00000196230, ENSG00000137285, ENSG00000123416, ENSG00000176014, ENSG00000137267, ENSG00000101162, ENSG00000258947, ENSG00000261456, ENSG00000188229, ENSG00000104833, ENSG00000127824, ENSG00000198033, ENSG00000167552, ENSG00000152086, ENSG00000141736",TRUE,TRUE,FALSE,FALSE,FALSE,"Antibody",FALSE
344,"Tafinlar","Dabrafenib","DABRAFENIB","GSK","CHEMBL2028663","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Oncology","S, O",2013,"ENSG00000157764",TRUE,FALSE,FALSE,FALSE,TRUE,"Small molecule",TRUE
345,"Mekinist","Trametinib","TRAMETINIB","GSK","CHEMBL2103875","MEK1 and MEK2 kinase inhibitor","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Oncology","S, O",2013,"ENSG00000169032, ENSG00000126934",TRUE,FALSE,FALSE,FALSE,TRUE,"Small molecule",TRUE
346,"Gilotrif","Afatinib","AFATINIB","Boehringer Ingelheim","CHEMBL1173655","EGFR (ERBB1), HER2 (ERBB2), and HER4 (ERRB4) kinase inhibitor","First-line treatment of patients with metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O",2013,"ENSG00000141736, ENSG00000146648, ENSG00000178568",TRUE,TRUE,FALSE,FALSE,TRUE,"Small molecule",FALSE
353,"Gazyva","Obinutuzumab","OBINUTUZUMAB","Genentech","CHEMBL1743048","Humanized CD20-specific monoclonal antibody","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Oncology","P, O, B",2013,"ENSG00000156738",TRUE,TRUE,TRUE,FALSE,TRUE,"Antibody",FALSE
355,"Imbruvica","Ibrutinib","IBRUTINIB","Pharmacyclics","CHEMBL1873475","Bruton's tyrosine kinase inhibitor","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Oncology","P, O, B",2013,"ENSG00000010671",TRUE,TRUE,TRUE,FALSE,TRUE,"Small molecule",FALSE
